Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
472.51
-1.49 (-0.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
You’ve Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.
June 27, 2024
Invest in the top biotech stocks to buy, as the sector pivots from pandemic-driven vaccine sales to solutions for chronic conditions.
Via
InvestorPlace
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
June 27, 2024
Via
Benzinga
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."
June 27, 2024
The biotech's shares have traded sideways for over a year, but better days could be on the near-term horizon.
Via
The Motley Fool
3 Biotech Stocks That Could Make Your Grandchildren Rich
June 27, 2024
These biotech stocks are poised to generate significant returns to investors due to their high growth potential.
Via
InvestorPlace
Peering Into Vertex Pharmaceuticals's Recent Short Interest
June 26, 2024
Via
Benzinga
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
June 25, 2024
It looks like Vertex's experimental new therapy could become a functional cure for lots of people with diabetes.
Via
The Motley Fool
Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX.
June 20, 2024
NASDAQ:VRTX is not too expensive for the growth it is showing.
Via
Chartmill
13 Analysts Have This To Say About Vertex Pharmaceuticals
June 17, 2024
Via
Benzinga
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
June 21, 2024
Lilly is a good pick...but this one is better.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
June 18, 2024
Via
Benzinga
3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation
June 18, 2024
Evergreen business models make it easier to hold for the long run.
Via
The Motley Fool
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
June 17, 2024
On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named ConocoPhillips, and Rob Sechan suggested AbbVie, with all four stocks having...
Via
Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
June 15, 2024
Want peace of mind about your investments? Consider these great stocks.
Via
The Motley Fool
Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)?
June 12, 2024
Why NASDAQ:VRTX Stands Out as a Quality Stock.
Via
Chartmill
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
June 05, 2024
Via
Benzinga
This Is What Whales Are Betting On Vertex Pharmaceuticals
June 03, 2024
Via
Benzinga
2 Healthcare Stocks to Buy Hand Over Fist in June
June 12, 2024
They both have pretty impressive pasts, and their prospects look just as bright.
Via
The Motley Fool
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
June 11, 2024
Via
Benzinga
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
June 10, 2024
Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services.
Via
Talk Markets
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
June 09, 2024
These companies could generate explosive growth over time.
Via
The Motley Fool
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
June 07, 2024
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety .
Via
Benzinga
Analyst Expectations For Vertex Pharmaceuticals's Future
May 31, 2024
Via
Benzinga
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable.
May 29, 2024
NASDAQ:VRTX is showing decent growth, but is still valued reasonably.
Via
Chartmill
Large Cap BIopharmaceuticals Overview
June 03, 2024
As a defensive play healthcare is weighted at about 12% of the S&P 500.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
3 No-Brainer Stocks to Buy in June
June 02, 2024
Now is the time to invest in these great stocks.
Via
The Motley Fool
5 Top Stocks to Buy in June
June 02, 2024
This medley of growth, value, and income stocks is poised to thrive long-term, even if the stock market sells off this summer.
Via
The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
June 01, 2024
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
A Very Bullish Reversal Produces A Huge Batch Of Actionable Stocks
May 31, 2024
It is very hard to get excited about what I'm seeing in the stock market because things have not been the way I've wanted them to be. In this video, I want to show you something as we look at a monthly...
Via
Talk Markets
Vertex Stock Recently Hit All-Time High, Leads 8 Top Performers New To IBD Stock Lists
May 31, 2024
Vertex stock was one of a select group of eight that made it onto IBD top-stocks lists Friday. The big pharma is near its all-time high.
Via
Investor's Business Daily
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
May 30, 2024
Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.